Literature DB >> 23744867

Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults.

Damon Reed1, Ragini Kudchadkar, Jonathan S Zager, Vernon K Sondak, Jane L Messina.   

Abstract

The rising incidence of melanoma in children has brought increased attention to the clinical and pathologic diagnosis of pigmented lesions in the pediatric age group. Although melanoma in infancy and early childhood is often associated with large congenital nevi, in older children and teenagers it is most often sporadic, occurring in patients with a low skin phototype and substantial sun exposure. The rarity of this potentially fatal disorder demands astute clinical attention and a high index of suspicion for atypical lesions in pediatric patients. The challenges include the difficult decision of whether to biopsy and an often equivocal pathologic diagnosis. These diagnostically challenging and equivocal lesions lead to a degree of uncertainty regarding additional workup, prognosis, potential therapy, and follow-up plans. Consultation with a specialty dermatopathologist can be very helpful, and advanced molecular diagnostic techniques may be used in selected circumstances. Although still controversial, good evidence exists to justify a role for sentinel lymph node biopsy. Patients with atypical melanocytic proliferations have a high rate of positive sentinel lymph nodes; however, their outcomes are clearly better than in similarly staged adults with conventional melanoma. With the multiple variables involved and the relative lack of prospectively derived evidence, clinical decision-making is challenging and patients and families may experience considerable stress. This article provides data and weighs the pros and cons of a rationale for decision-making in pediatric and young adult patients with diagnostically challenging melanocytic lesions.

Entities:  

Mesh:

Year:  2013        PMID: 23744867      PMCID: PMC4530628          DOI: 10.6004/jnccn.2013.0087

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  66 in total

1.  Giant pigmented nevi: clinical, histopathologic, and therapeutic considerations.

Authors:  R Ruiz-Maldonado; L Tamayo; A M Laterza; C Durán
Journal:  J Pediatr       Date:  1992-06       Impact factor: 4.406

2.  Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair.

Authors:  Porcia T Bradford; Alisa M Goldstein; Deborah Tamura; Sikandar G Khan; Takahiro Ueda; Jennifer Boyle; Kyu-Seon Oh; Kyoko Imoto; Hiroki Inui; Shin-Ichi Moriwaki; Steffen Emmert; Kristen M Pike; Arati Raziuddin; Teri M Plona; John J DiGiovanna; Margaret A Tucker; Kenneth H Kraemer
Journal:  J Med Genet       Date:  2010-11-19       Impact factor: 6.318

3.  High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696.

Authors:  J M Kirkwood; J Ibrahim; D H Lawson; M B Atkins; S S Agarwala; K Collins; R Mascari; D M Morrissey; P B Chapman
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

4.  The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma.

Authors:  Fariba Navid; Wayne L Furman; Martin Fleming; Bhaskar N Rao; Sandra Kovach; Catherine A Billups; Alvida M Cain; Rex Amonette; Jesse J Jenkins; Alberto S Pappo
Journal:  Cancer       Date:  2005-02-15       Impact factor: 6.860

5.  Sentinel node biopsy in atypical melanocytic neoplasms in childhood: a single institution experience in 24 patients.

Authors:  Omie L Mills; Suroosh Marzban; Jonathan S Zager; Vernon K Sondak; Jane L Messina
Journal:  J Cutan Pathol       Date:  2012-03       Impact factor: 1.587

6.  Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study.

Authors:  Sandra L Wong; Donald L Morton; John F Thompson; Jeffrey E Gershenwald; Stanley P L Leong; Douglas S Reintgen; Haim Gutman; Michael S Sabel; Grant W Carlson; Kelly M McMasters; Douglas S Tyler; James S Goydos; Alexander M M Eggermont; Omgo E Nieweg; A Benedict Cosimi; Adam I Riker; Daniel G Coit
Journal:  Ann Surg Oncol       Date:  2006-04-12       Impact factor: 5.344

7.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

8.  Trends in pediatric melanoma mortality in the United States, 1968 through 2004.

Authors:  Kevan G Lewis
Journal:  Dermatol Surg       Date:  2007-12-17       Impact factor: 3.398

9.  Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma?

Authors:  Christiane A Voit; Alexander C J van Akkooi; Gregor Schäfer-Hesterberg; Alfred Schoengen; Paul I M Schmitz; Wolfram Sterry; Alexander M M Eggermont
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

10.  The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution.

Authors:  Mathew W Ludgate; Douglas R Fullen; Julia Lee; Lori Lowe; Carol Bradford; James Geiger; Jennifer Schwartz; Timothy M Johnson
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

View more
  7 in total

Review 1.  [Expression of cancer testis (CT) antigens in pediatric and adolescent melanomas].

Authors:  N Behrendt; T Schultewolter; K Busam; D Frosina; G Spagnoli; A Jungbluth
Journal:  Pathologe       Date:  2017-07       Impact factor: 1.011

2.  Spitzoid melanoma of childhood: a case series and review.

Authors:  Sandeep Batra
Journal:  Melanoma Manag       Date:  2015-05-18

3.  Pediatric melanoma and aggressive Spitz tumors: a retrospective diagnostic, exposure and outcome analysis.

Authors:  Kelly M Bailey; Alison B Durham; Lili Zhao; Doug Fullen; James Geiger; Carol Bradford; Valerie Opipari; Timothy Johnson; Rajen Mody
Journal:  Transl Pediatr       Date:  2018-07

4.  TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms.

Authors:  Seungjae Lee; Raymond L Barnhill; Reinhard Dummer; James Dalton; Jianrong Wu; Alberto Pappo; Armita Bahrami
Journal:  Sci Rep       Date:  2015-06-10       Impact factor: 4.379

5.  Fluorescence in situ hybridization analysis of atypical melanocytic proliferations and melanoma in young patients.

Authors:  Emilia H DeMarchis; Susan M Swetter; Charay D Jennings; Jinah Kim
Journal:  Pediatr Dermatol       Date:  2014-06-13       Impact factor: 1.588

6.  The landscape of fusion transcripts in spitzoid melanoma and biologically indeterminate spitzoid tumors by RNA sequencing.

Authors:  Gang Wu; Raymond L Barnhill; Seungjae Lee; Yongjin Li; Ying Shao; John Easton; James Dalton; Jinghui Zhang; Alberto Pappo; Armita Bahrami
Journal:  Mod Pathol       Date:  2016-02-19       Impact factor: 7.842

7.  Genomic analysis and clinical management of adolescent cutaneous melanoma.

Authors:  Roy Rabbie; Mamunur Rashid; Ana M Arance; Marcelo Sánchez; Gemma Tell-Marti; Miriam Potrony; Carles Conill; Remco van Doorn; Stefan Dentro; Nelleke A Gruis; Pippa Corrie; Vivek Iyer; Carla Daniela Robles-Espinoza; Joan A Puig-Butille; Susana Puig; David J Adams
Journal:  Pigment Cell Melanoma Res       Date:  2017-04-19       Impact factor: 4.693

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.